# sEcad as a novel target and therapy for IGF-1R expressing tumors

> **NIH NIH R01** · STATE UNIVERSITY NEW YORK STONY BROOK · 2022 · $398,750

## Abstract

ABSTRACT
Breast cancer and Alzheimer's disease (AD) are common diseases of aging, and independently are
responsible for significant morbidity and mortality in the United States. Recent clinical studies and large
prospective population-based analyses have surprisingly suggested the presence of an inverse association
between cancer and Alzheimer Disease (AD), one where cancer decreases the risk of development of
dementia, and even AD. Other studies, however, have reported that breast cancer survivors demonstrate a
significantly higher probability for AD, and implicated the ApoE e4 allele specifically in this interconnection.
Therefore, the role of cancer in AD development remains highly controversial. Moreover, the mechanisms
responsible for this interconnection remain largely unknown. It is the goal of this administrative supplement to
R01CA194409, entitled “sEcad as a novel target and therapy for IGF-1R expressing tumors”, to investigate
whether the development of breast cancer, with and without the benefit of our tumor-targeting anti-sEcad
antibodies, have an impact on Alzheimer's disease in the novel APP/PS1;Neu compound transgenic mouse
which develops both AD (APP/PS1 allele) and breast cancer (MMTV-Neu). To this end, we will temporally
evaluate alterations in Aβ pathology, neuroinflammation and cognitive function in the APP/PS1;Neu double
transgenic mouse model, which temporally compounds breast cancer and AD pathology.
Heath Impact: The proposed administrative supplement will begin to address the very significant question of
whether breast cancer has an impact on AD development, and enable the elucidation of mechanisms
underlying such a putative interconnection. Completion of the proposed studies will provide the preliminary
data necessary for future R01 grant applications.
.

## Key facts

- **NIH application ID:** 10498219
- **Project number:** 3R01CA194409-08S1
- **Recipient organization:** STATE UNIVERSITY NEW YORK STONY BROOK
- **Principal Investigator:** Sabine M Brouxhon
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $398,750
- **Award type:** 3
- **Project period:** 2015-09-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10498219

## Citation

> US National Institutes of Health, RePORTER application 10498219, sEcad as a novel target and therapy for IGF-1R expressing tumors (3R01CA194409-08S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10498219. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*